Targeting Metabolic Reprogramming in Polycystic Kidney Disease.
作者信息
Boletta Alessandra
机构信息
Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
出版信息
J Am Soc Nephrol. 2024 Dec 1;35(12):1768-1770. doi: 10.1681/ASN.0000000507. Epub 2024 Sep 3.
Abstract
摘要
相似文献
1
Targeting Metabolic Reprogramming in Polycystic Kidney Disease.针对多囊肾病中的代谢重编程
J Am Soc Nephrol. 2024 Dec 1;35(12):1768-1770. doi: 10.1681/ASN.0000000507. Epub 2024 Sep 3.
2
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.常染色体显性遗传多囊肾病中的代谢重编程：证据与治疗潜力。
Clin J Am Soc Nephrol. 2020 Apr 7;15(4):577-584. doi: 10.2215/CJN.13291019. Epub 2020 Feb 21.
3
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Role in Cystogenesis and Novel Therapeutic Approaches.常染色体显性多囊肾病中的代谢重编程：在囊肿形成中的作用及新的治疗方法
Biomedicines. 2025 Jun 30;13(7):1596. doi: 10.3390/biomedicines13071596.
4
GLIS3: A novel transcriptional regulator of mitochondrial functions and metabolic reprogramming in postnatal kidney and polycystic kidney disease.GLIS3：出生后肾脏及多囊肾病中线粒体功能和代谢重编程的新型转录调节因子。
Mol Metab. 2024 Dec;90:102052. doi: 10.1016/j.molmet.2024.102052. Epub 2024 Nov 5.
5
Mitochondrial metabolic reprogramming in diabetic kidney disease.糖尿病肾病中的线粒体代谢重编程。
Cell Death Dis. 2024 Jun 24;15(6):442. doi: 10.1038/s41419-024-06833-0.
6
Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.多囊肾病同源模型中缓慢发展的代谢重编程。
Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F258-F267. doi: 10.1152/ajprenal.00262.2021. Epub 2022 Jan 17.
7
Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan.常染色体显性多囊肾病的治疗：超越托伐普坦
Curr Opin Nephrol Hypertens. 2025 Sep 1;34(5):368-374. doi: 10.1097/MNH.0000000000001101. Epub 2025 Jul 4.
8
Super-enhancer-driven metabolic reprogramming promotes cystogenesis in autosomal dominant polycystic kidney disease.
Nat Metab. 2020 Aug;2(8):717-731. doi: 10.1038/s42255-020-0227-4. Epub 2020 Jul 13.
9
Metabolism-based approaches for autosomal dominant polycystic kidney disease.基于代谢的常染色体显性多囊肾病治疗方法。
Front Mol Biosci. 2023 Feb 16;10:1126055. doi: 10.3389/fmolb.2023.1126055. eCollection 2023.
10
Metabolic reprogramming in polycystic kidney disease and other renal ciliopathies.多囊肾病及其他肾脏纤毛病中的代谢重编程。
EMBO Mol Med. 2025 Apr 22. doi: 10.1038/s44321-025-00239-x.
本文引用的文献
1
Inhibition of asparagine synthetase effectively retards polycystic kidney disease progression.抑制天冬酰胺合成酶能有效延缓多囊肾病的进展。
EMBO Mol Med. 2024 Jun;16(6):1379-1403. doi: 10.1038/s44321-024-00071-9. Epub 2024 Apr 29.
2
Polycystic kidney disease.多囊肾病。
Nat Rev Dis Primers. 2018 Dec 6;4(1):50. doi: 10.1038/s41572-018-0047-y.
3
Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways.多囊肾病中代谢重编程的剖析揭示了生物能量途径的协同重塑。
Commun Biol. 2018 Nov 16;1:194. doi: 10.1038/s42003-018-0200-x. eCollection 2018.
4
2-Deoxy-d-Glucose Ameliorates PKD Progression.2-脱氧-D-葡萄糖可改善多囊肾病的进展。
J Am Soc Nephrol. 2016 Jul;27(7):1958-69. doi: 10.1681/ASN.2015030231. Epub 2015 Nov 3.
5
Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.多囊肾病中葡萄糖代谢缺陷为新的治疗策略提供了依据。
Nat Med. 2013 Apr;19(4):488-93. doi: 10.1038/nm.3092. Epub 2013 Mar 24.
6
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.一项单独使用 2-脱氧-D-葡萄糖或与多西他赛联合用于晚期实体瘤患者的 I 期剂量递增试验。
Cancer Chemother Pharmacol. 2013 Feb;71(2):523-30. doi: 10.1007/s00280-012-2045-1. Epub 2012 Dec 11.
7
Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure.成年期主要器官和组织的特定代谢率：通过静息能量消耗的机制模型评估。
Am J Clin Nutr. 2010 Dec;92(6):1369-77. doi: 10.3945/ajcn.2010.29885. Epub 2010 Oct 20.
8
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.癌症生物学：代谢重编程推动细胞生长和增殖。
Cell Metab. 2008 Jan;7(1):11-20. doi: 10.1016/j.cmet.2007.10.002.
9
The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.人类I型常染色体显性多囊肾病中局灶性囊肿形成的分子基础。
Cell. 1996 Dec 13;87(6):979-87. doi: 10.1016/s0092-8674(00)81793-6.
10
Polycystic kidney disease: neoplasia in disguise.多囊肾病：伪装成肿瘤的疾病。
Am J Kidney Dis. 1990 Feb;15(2):110-6. doi: 10.1016/s0272-6386(12)80507-5.
Zotero 插件